Editorial

DOI: 10.4244/EIJ-E-24-00067

Myval transcatheter heart valve system: a new TAVI contender and remaining uncertainties

Stephan Windecker1, MD; Daijiro Tomii1, MD

Transcatheter aortic valve implantation (TAVI) has evolved into a transformative alternative to surgical aortic valve replacement (SAVR), supported by robust evidence from numerous randomised clinical trials across the spectrum of surgical risk, and features two landmark transcatheter heart valve (THV) devices: the balloon-expandable SAPIEN (Edwards Lifesciences) and the self-expanding CoreValve/Evolut (Medtronic) series. Against this solid evidence base, novel THV technologies are increasingly tested in head-to-head comparisons against these established balloon-expandable and self-expanding valve standards of care (Figure 1)12345. In the recently published LANDMARK trial, a novel balloon-expandable prosthesis, the Myval THV (Meril Life Sciences), was directly compared with contemporary THVs (SAPIEN and Evolut series)4. Of note, the Myval THV introduces a sizing strategy with 1.5 mm diameter increments between nominal device sizes, allowing for a more nuanced sizing strategy to match the aortic annulus compared to conventional devices with fixed 3.0 mm diameter increments. Out of 5,109 screened patients, 768 patients deemed eligible for all three devices were randomly assigned 1:1 to Myval (N=384) or to contemporary THVs (N=384) with subsequent stratification...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 21 Number 2
Jan 20, 2025
Volume 21 Number 2
View full issue


Key metrics

Trending articles
95.7

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
67.15

State-of-the-Art

10.4244/EIJ-D-24-00992 Sep 15, 2025
Antithrombotic therapy in complex percutaneous coronary intervention
Castiello D et al
free
56.1

Original Research

10.4244/EIJ-D-25-00331 May 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
56.1

Original Research

10.4244/EIJ-D-25-00331 Jul 21, 2025
One-month dual antiplatelet therapy followed by prasugrel monotherapy at a reduced dose: the 4D-ACS randomised trial
Jang Y et al
open access
35.45

State-of-the-Art

10.4244/EIJ-D-23-00448 Jan 15, 2024
Coronary spasm and vasomotor dysfunction as a cause of MINOCA
Yaker ZS et al
free
X

PCR
Impact factor: 9.5
2024 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2025)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved